Patents by Inventor Solomon Langermann

Solomon Langermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210363240
    Abstract: Compositions and methods of use thereof for modulating LAIR-1 are provided. For example, immunomodulatory agents are provided that reduce LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Exemplary agents include (i) a soluble LAIR-2 polypeptide or fusion protein, (ii) a soluble LAIR-1 polypeptide or fusion protein, (iii) a function blocking anti-LAIR-1 antibody, (iv) an antibody that depletes LAIR-1 positive cells, and (y) combinations thereof. Immunomodulatory agents are also provided that increase LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof. Exemplary agents include: (i) a function activating anti-LAIR-1 antibody, (ii) a function blocking anti-LAIR-2 antibody, and (iii) a combination thereof.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 25, 2021
    Inventors: Dallas Benjamin Flies, Linda Liu, Solomon Langermann
  • Publication number: 20210032346
    Abstract: Compositions and methods of use thereof for modulating B7-H4 are provided. For example, immunomodulatory agents are provided that reduce B7-H4 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Immunomodulatory agents are also provided that increase B7-H4 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof.
    Type: Application
    Filed: January 23, 2019
    Publication date: February 4, 2021
    Inventors: Solomon Langermann, Dallas Benjamin Flies, Linda LIU
  • Publication number: 20190202912
    Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.
    Type: Application
    Filed: September 21, 2017
    Publication date: July 4, 2019
    Inventors: Linda Liu, Benjamin Dallas Flies, Solomon Langermann
  • Patent number: 10316092
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: June 11, 2019
    Assignees: THE JOHN HOPKINS UNIVERSITY, MEDIMMUNE, LLC
    Inventors: Sheng Yao, Lieping Chen, Linda Liu, Solomon Langermann
  • Patent number: 9957312
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 1, 2018
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Publication number: 20180079813
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 22, 2018
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
  • Publication number: 20180066056
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 8, 2018
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
  • Patent number: 9790277
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 17, 2017
    Assignees: The Johns Hopkins University, MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen
  • Patent number: 9676854
    Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: June 13, 2017
    Assignee: MedImmune, LLC
    Inventors: Linda Liu, Shannon Marshall, Solomon Langermann
  • Patent number: 9574000
    Abstract: Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immunospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 21, 2017
    Assignees: MedImmune, LLC, The Johns Hopkins University
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen, Michael Glen Overstreet
  • Publication number: 20160146806
    Abstract: Isolated cell surface receptors for B7-H4 have been identified based on function. B7-H4 receptor activation by B7-H4 on the dendritic cell, T follicular helper cell and germinal center B cell membrane stimulates inhibitory signaling in those leukocytes. B7-H4 receptor activation decreases production and/or secretion of proinflammatory cytokines, and promotes anti-inflammatory cytokine by mature DC and T cells. Modulators of B7-H4 receptor polypeptides and methods for their therapeutic use are also provided.
    Type: Application
    Filed: May 19, 2014
    Publication date: May 26, 2016
    Inventors: Solomon Langermann, Joseph R. Podojil, Stephen D. Miller
  • Publication number: 20160130348
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: May 12, 2016
    Inventors: Solomon Langermann, Linda Liu, Shannon Marshall, Sheng Yao
  • Publication number: 20160096891
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 7, 2016
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: LIEPING CHEN, SHENG YAO, LINDA LIU, SOLOMON LANGERMANN
  • Publication number: 20160039906
    Abstract: Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.
    Type: Application
    Filed: April 6, 2015
    Publication date: February 11, 2016
    Inventors: Solomon Langermann, Linda Liu
  • Publication number: 20160039905
    Abstract: Fusion proteins containing B7-II4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by Th1, Th1 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Application
    Filed: April 6, 2015
    Publication date: February 11, 2016
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Publication number: 20160024210
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: December 23, 2013
    Publication date: January 28, 2016
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen
  • Patent number: 9205148
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: December 8, 2015
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Shannon Marshall, Sheng Yao
  • Publication number: 20150315275
    Abstract: Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immmospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 5, 2015
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen, Michael Glen Overstreet
  • Patent number: 9011853
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: April 21, 2015
    Assignee: Amplimmune, Inc.
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Patent number: 9005616
    Abstract: Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: April 14, 2015
    Assignee: Amplimmune, Inc.
    Inventors: Solomon Langermann, Linda Liu